EA200400793A1 - Применение ингибиторов обратного захвата норэпинефрина для лечения нарушения познавательной функции - Google Patents

Применение ингибиторов обратного захвата норэпинефрина для лечения нарушения познавательной функции

Info

Publication number
EA200400793A1
EA200400793A1 EA200400793A EA200400793A EA200400793A1 EA 200400793 A1 EA200400793 A1 EA 200400793A1 EA 200400793 A EA200400793 A EA 200400793A EA 200400793 A EA200400793 A EA 200400793A EA 200400793 A1 EA200400793 A1 EA 200400793A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitors
norepinefrin
application
cognitive function
reverse capture
Prior art date
Application number
EA200400793A
Other languages
English (en)
Russian (ru)
Inventor
Фрэнклин Портер Баймастер
Дональд Ричард Гелерт
Дэвид Ли Маккинзи
Чарльз Ренкин Янг
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200400793A1 publication Critical patent/EA200400793A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EA200400793A 2001-12-11 2002-11-27 Применение ингибиторов обратного захвата норэпинефрина для лечения нарушения познавательной функции EA200400793A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33917401P 2001-12-11 2001-12-11
PCT/US2002/036132 WO2003049724A1 (en) 2001-12-11 2002-11-27 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure

Publications (1)

Publication Number Publication Date
EA200400793A1 true EA200400793A1 (ru) 2004-10-28

Family

ID=23327833

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200400793A EA200400793A1 (ru) 2001-12-11 2002-11-27 Применение ингибиторов обратного захвата норэпинефрина для лечения нарушения познавательной функции

Country Status (26)

Country Link
US (1) US20050009925A1 (cg-RX-API-DMAC10.html)
EP (1) EP1458368B1 (cg-RX-API-DMAC10.html)
JP (1) JP2005517647A (cg-RX-API-DMAC10.html)
KR (1) KR20040066895A (cg-RX-API-DMAC10.html)
CN (1) CN1713900A (cg-RX-API-DMAC10.html)
AU (1) AU2002352625A1 (cg-RX-API-DMAC10.html)
BR (1) BR0213581A (cg-RX-API-DMAC10.html)
CA (1) CA2467802A1 (cg-RX-API-DMAC10.html)
CO (1) CO5590907A2 (cg-RX-API-DMAC10.html)
CZ (1) CZ2004709A3 (cg-RX-API-DMAC10.html)
DE (1) DE60223718T2 (cg-RX-API-DMAC10.html)
EA (1) EA200400793A1 (cg-RX-API-DMAC10.html)
EC (1) ECSP045145A (cg-RX-API-DMAC10.html)
ES (1) ES2295435T3 (cg-RX-API-DMAC10.html)
HR (1) HRPK20040528B3 (cg-RX-API-DMAC10.html)
HU (1) HUP0402619A3 (cg-RX-API-DMAC10.html)
IL (1) IL161989A0 (cg-RX-API-DMAC10.html)
MX (1) MXPA04005716A (cg-RX-API-DMAC10.html)
MY (1) MY136367A (cg-RX-API-DMAC10.html)
NO (1) NO20042904L (cg-RX-API-DMAC10.html)
NZ (1) NZ532065A (cg-RX-API-DMAC10.html)
PL (1) PL369311A1 (cg-RX-API-DMAC10.html)
SK (1) SK2442004A3 (cg-RX-API-DMAC10.html)
TW (1) TW200300672A (cg-RX-API-DMAC10.html)
WO (1) WO2003049724A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200404274B (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05001705A (es) * 2002-08-14 2005-04-19 Pharmacia & Upjohn Co Llc Uso de reboxetina para el tratamiento de sofocos.
WO2005011583A2 (en) * 2003-07-28 2005-02-10 Leslie Joe Dunaway Treatment of allergic rhinitis and asthma
US20070105960A1 (en) * 2003-08-27 2007-05-10 Eli Lilly And Company Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
KR20060121178A (ko) * 2003-12-12 2006-11-28 일라이 릴리 앤드 캄파니 일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제
AP2006003771A0 (en) * 2004-04-30 2006-10-31 Warner Lambert Co Substituted morpholine compounds for the treatmentof central nervous system disorders
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US20100317730A1 (en) * 2009-06-12 2010-12-16 Shaya Elias K Treatment for menopausal and perimenopausal vasomotor symptons
TW201107485A (en) * 2009-07-31 2011-03-01 Univ Nat Taiwan Treating negative symptoms of schizophrenia associated with defective neuregulin 1 (NRG1)
US20140249180A1 (en) * 2011-10-03 2014-09-04 National Center For Geriatrics And Gerontology Tau aggregation inhibitor
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP2962687B1 (en) 2013-04-02 2019-06-05 The Doshisha Tau aggregation inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
ATE305788T1 (de) * 1999-07-01 2005-10-15 Pharmacia & Upjohn Co Llc (s,s)-reboxetin zur behandlung von inkontinenz
SK4732002A3 (en) * 1999-10-13 2002-12-03 Pfizer Prod Inc Biaryl ether derivatives useful as monoamine reuptake inhibitors
WO2002053104A2 (en) * 2001-01-02 2002-07-11 Sention, Inc. Use of catecholamine reuptake inhibitors to enhance memory
MXPA03006003A (es) * 2001-01-02 2005-09-08 Upjohn Co Nuevas combinaciones de farmacos.

Also Published As

Publication number Publication date
PL369311A1 (en) 2005-04-18
NO20042904L (no) 2004-09-07
JP2005517647A (ja) 2005-06-16
AU2002352625A1 (en) 2003-06-23
ES2295435T3 (es) 2008-04-16
SK2442004A3 (en) 2004-12-01
MY136367A (en) 2008-09-30
MXPA04005716A (es) 2004-12-06
CN1713900A (zh) 2005-12-28
HUP0402619A3 (en) 2008-04-28
BR0213581A (pt) 2004-08-24
CZ2004709A3 (cs) 2004-10-13
HUP0402619A2 (hu) 2005-03-29
EP1458368B1 (en) 2007-11-21
EP1458368A1 (en) 2004-09-22
ZA200404274B (en) 2005-09-13
HRPK20040528B3 (en) 2006-03-31
NZ532065A (en) 2007-03-30
US20050009925A1 (en) 2005-01-13
DE60223718D1 (de) 2008-01-03
DE60223718T2 (de) 2008-10-30
CO5590907A2 (es) 2005-12-30
KR20040066895A (ko) 2004-07-27
WO2003049724A1 (en) 2003-06-19
CA2467802A1 (en) 2003-06-19
TW200300672A (en) 2003-06-16
ECSP045145A (es) 2004-07-23
HRP20040528A2 (en) 2004-10-31
IL161989A0 (en) 2005-11-20

Similar Documents

Publication Publication Date Title
BR0206422B1 (pt) mÉtodo e instalaÇço industrial para espessamento de lamas derivadas de tratamento de Águas atravÉs de floculaÇço-decantaÇço com floco lastreado.
EP1463531A4 (en) PROCESS FOR INHIBITING OKULAR PROCESSES
DE60237725D1 (de) Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit
DE60101265D1 (de) Behandlung von augenschmerzen
DE60238898D1 (de) Oxidative Zusammensetzung zur Behandlung von Keratinfasern, die spezielle Aminosilikone enthält
DE60231107D1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
EA200401341A1 (ru) Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания
EE200400005A (et) Tablett, mis sisaldab vähemalt kahte eristatavat segmenti ning selle kasutamine
DE60220043D1 (de) Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen
NL1021504A1 (nl) Waterstofbehandelingsproces.
EA200600896A1 (ru) Способ лечения раздражения мочевого пузыря и чрезмерно активного мочевого пузыря
DK1408976T3 (da) Behandling af ADHD (Attention deficit hyperactivity disorder)
ITTO20010848A0 (it) Disposizione e metodo di purificazione o trattamento elettrochimico.
EP1359885A4 (en) NOS-HEMMER FOR THE TREATMENT OF WRINKLES
EA200501528A1 (ru) Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний
MY136367A (en) Treatment of cognitive failure
DE60219687D1 (de) Aroylpyrrolheteroeryl und methanole zur behandlung von störungen des zentralnervensystems
PT102870A (pt) Metodo de tratamento de condensados
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
EA200601238A1 (ru) Медикаменты для профилактики и лечения бромидроза и для улучшения запаха тела
DK1438034T3 (da) Anvendelse af -phenyl-3-dimethylaminiopropanforbindelser til behandling af urininkontinens
WO2002040006A3 (en) Treatment of anxiety disorders
FI20040531A7 (fi) Insuliiniresistenttien tilojen hoitaminen ja diagnosointi
EA200501259A1 (ru) Комбинированное применение фибрата и орлистата для лечения ожирения
DK1455770T3 (da) Anvendelse af norepinephringenoptagelsesinhibitorer til behandling af tic lidelser